MoonLake Immunotherapeutics Under Legal Scrutiny
MoonLake Immunotherapeutics is currently facing a class action lawsuit that has been brought forth by Bragar Eagel & Squire, P.C., a respected law firm specializing in shareholder rights. This lawsuit pertains to the company's common stock, and it is important for investors who may have purchased shares of MoonLake between specific dates to understand their rights and available options.
Understanding Your Rights as an Investor
If you've invested in MoonLake Immunotherapeutics (NASDAQ: MLTX), particularly in the time frame spanning from March 10, 2024, to September 29, 2025, this information is relevant for you. Legal representation is available for all individuals who believe they may have been adversely affected by the actions of the company during this period. The firm is encouraging those who have experienced losses to reach out for consultation.
Class Action Timeline
Investors have until December 15, 2025, to apply to be designated as lead plaintiffs in the class action lawsuit. Acting promptly is advisable for anyone considering their participation in this action, as timelines are critical in legal matters.
Key Allegations Against MoonLake
The crux of the allegations against MoonLake Immunotherapeutics revolves around the misleading promotion of its flagship drug candidate, sonelokimab (SLK). The company has been accused of overstating SLK's efficacy compared to competing drugs, particularly UCB's BIMZELX. The lawsuit claims that the executives of MoonLake presented SLK as having distinct advantages that were unwarranted.
Impact on Shareholder Value
On September 28, 2025, negative news regarding the results of a Phase 3 clinical trial for sonelokimab became public, which indicated that the drug did not perform as well as reported against BIMZELX. This disclosure led to a staggering drop in MoonLake's stock price, plummeting nearly 90%, which resulted in worst-case scenarios for numerous investors.
What Investors Should Do Next?
For anyone who purchased MoonLake shares and suffered a financial setback due to this situation, it is critical to seek advice. Reaching out for professional guidance can provide clarity on your legal standing. Potential claimants are encouraged to contact Brandon Walker or Marion Passmore from Bragar Eagel & Squire, P.C. via phone or email. They are readily available to assist with understanding the implications of the lawsuit and any potential next steps.
About Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire is a law firm known for its commitment to protecting investors’ rights. With a broad expertise spanning numerous areas of litigation including securities, they serve clients nationwide from their offices located in several states. For those wishing to learn more about the firm’s work and past cases, additional resources are available through their website.
Frequently Asked Questions
What is the main allegation against MoonLake Immunotherapeutics?
The lawsuit alleges that MoonLake misrepresented its drug candidate sonelokimab's efficacy compared to competing products, leading to significant investor losses.
Who can join the class action lawsuit?
Individuals who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, are eligible to join the lawsuit.
What should I do if I lost money investing in MoonLake?
Investors should consider contacting Bragar Eagel & Squire for an evaluation of their case and the potential for joining the class action.
How long do I have to join the lawsuit?
Investors have until December 15, 2025, to apply to be a lead plaintiff in the class action lawsuit.
Where can I get more information about Bragar Eagel & Squire?
More details regarding their services and prior cases can be found on their official website.
